TMS Nearby

Spravato (Esketamine) in El Paso, Texas

Compare 2 Spravato (Esketamine) clinics in El Paso, Texas that offer care for treatment-resistant depression and major depressive disorder. Review services, ratings, and contact details to find the right provider near you.
Mental health clinic illustration

Clinics

2 clinics shown

  • El Paso Behavioral Health System

    Inpatient and outpatient psychiatric services are provided at El Paso Behavioral Health System on Denver Avenue for adults and adolescents experiencing acute mental health crises or requiring structured treatment. The facility offers psychiatric evaluations, medication management, and therapeutic programming for conditions including depression, bipolar disorder, anxiety disorders, and psychosis. Admissions occur 24/7 through the emergency assessment center, with treatment plans developed by multidisciplinary teams including psychiatrists, therapists, and nursing staff. Specific procedural treatments such as TMS or esketamine are not detailed in available information.

    No reviews yet
    View Details

  • La Mente Behavioral Health

    La Mente Behavioral Health operates a mental health clinic in El Paso on Montana Avenue, with entrance access via Buffalo Soldier Drive. The practice provides outpatient psychiatric services for adults and adolescents in the El Paso region. Specific treatment modalities such as TMS, ketamine, or esketamine are not detailed in available information; prospective patients should contact the clinic to confirm available services and insurance acceptance.

    No reviews yet
    View Details

About Spravato (Esketamine)

Spravato is the brand name for esketamine, an FDA-approved nasal spray for treatment-resistant depression and major depressive disorder with suicidal ideation. It's derived from ketamine and works on the brain's glutamate system — a different mechanism than traditional antidepressants like SSRIs.

Treatment is administered only at REMS-certified clinics under direct medical supervision. Patients self-administer the spray under a clinician's guidance, then remain at the clinic for at least two hours of monitoring after each dose. The induction phase typically involves twice-weekly sessions for four weeks, followed by weekly or biweekly maintenance dosing depending on response.

Many patients report meaningful symptom improvement within the first one to two weeks — substantially faster than the 4 to 8 weeks typical of oral antidepressants. Spravato is taken alongside an oral antidepressant, not as a replacement.

The most common side effects are dissociation, dizziness, sedation, and elevated blood pressure during and shortly after dosing. These typically resolve within the two-hour monitoring window. Patients cannot drive on the day of treatment.

Most commercial insurance and Medicare cover Spravato for treatment-resistant depression with prior authorization. Clinics offering Spravato in our directory hold active REMS certification and are staffed to provide the required in-clinic monitoring period.